Kyo-kyo-kuman has not been analyzed with modern medicine methods. We hypothesize that Kyo-kyo-kuman reflects the severity of somatization symptoms. Thus we investigated the correlation of Kyo-kyo-kuman with somatization symptoms, using Keio's Kyo-kyo-kuman scale (K-scale) and the Screener for Somatoform Disorders (SSD). One hundred and fifty patients (38 males, 112 females, mean age 40.69±17.56 years) were evaluated for their Kyo-kyo-kuman levels, using the K-scale and the number of somatization symptoms according to the SSD. On the right, the K-scale scores correlated significantly with the number of present somatization symptoms (R=0.440, p<0.0001) and the number of somatization symptoms within one year (R=0.476, p<0.0001). On the left, the K-scale scores correlated significantly with the number of somatization symptoms lasting for more than three months (R=0.450, p<0.0001), the number of present somatization symptom (R=0.597, p<0.0001) and the number of somatization symptoms within one year (R=0.586, p<0.0001).
In conclusion, patients having Kyo-kyo-kuman tended to complain of many kinds of somatization symptoms. We suggest that Kyo-kyo-kuman correlates well with these symptoms.

A new 5a, 8a - epidioxy sterol named Axinysasterol (1) with a known compound (6R, 7S)-7-amino-7, 8-dihydro-a-bisaboIene hydrochloride (2) was isolated from the Okinawa marine sponge Axinyssa sp. The structure of Axinysasterol (1) deduced as 5a, 8a-epidioxyergosta - 6,22,25-trien-3B-ol on the basis of chemical and spectral evidence.

Because of geographical conditions in Japan, most of our rice is grown in paddies. It is very hard to work in paddies wearing a prosthesis.
The type of prosthesis, called the “DOLINGEL” or “Iron Leg”, are not suitable in paddies. The followings were our research and development objections;
1. To select strong light materials and design for the new prosthesis.
2. To have a simple design which could be cleaned easily after use.
3. To consider the problem of skin irritation on the stump end.
4. To select the best foot shape for easy lifting from the mud. From the above objectives, we improved it after actual use.
A summary of our improvement;
Aluminium was used as the main material for its light weight. The lower leg was made of plastic for its ease of clearing.
Regarding the knee joint settlement during work;
The old prosthesis was too unsteady to permit the worker to carry things. So we reconstructed it. By bending it forward, putting a long boot on the prosthesis was very easier. We used a system where by the whole lower leg section can be changed by a “one touch” prosedure. We put rubber on the sole to prevent slipping. We put a belt on the affected side. Its design is the result of our experiments and of actual field use.

In order to determine the effectiveness of Orengedoku-to in the treatment of schizophrenia, Orengedoku-to was added to the drug regimens of 10 patients who had been hospitalized with onset episodes or acute exacerbation of this condition. Before Orengedoku-to was added, the schizophrenic symptoms associated with the active phase had already been ameliorated with administration of antipsychotic drugs such as haloperidol for 4-12 weeks, with administration continuing at least two weeks after these symptoms had stabilized. Symptoms were evaluated using the Brief Psychiatric Rating Scale (BPRS) three times: before Orengedoku-to was added, immediately following cessation of administration, and four weeks after administration had ended. The BPRS scores indicated significant decreases both immediately following cessation of administration and four weeks later (from 36.3±9.8 to 30.5±6.7). In particular, significant improvement was noted for the symptoms of guilt feelings, depressive mood, suspiciousness and excitement. These improvements were not thought to be due to haloperidol, because the plasma haloperridol levels did not change. No adverse effects were noted.

We investigated the change of “Kyo-kyo-kuman, ” after the administration of Saiko-zai (including Bupleuri Radix) or Non-saiko-zai (not including Bupleuri Radix). Subjects were 44 patients (7 males, 37 females, with a mean age of 42.8±16.4). We evaluated their levels of the Kyo-kyo-kuman, with blood biochemical tests, their depressive levels using Zung's Self Depression Scale (SDS), and their subjective well-being levels using the Subjective Well-being Inventory (SUBI) scale, at baseline and 3 and 6 months after the administration of Kampo formula. In the S-group (20 patients), administered Saiko-zai for 6 months, the K-scale (Keio's Kyo-kyo-kuman scale) scores showed significant decreases at 3 and 6 months. In the C-group (16 patients), administered Non-saiko-zai for 6 months, the K-scale scores did not change significantly. There was a statistically significant decrease in the K-scale scores of the patients of S-group as compared to the patients of C-group. The decreases in the left K-scale scores correlated significantly with the rises in plasma protein concentrations.

　　The platelet counts documented in most of the studies using the fully automated hematology analyzer XE-5000 are values measured by impedance technology (PLT-I). If blood specimens showing an anomalous particle-size distribution curve in the area where platelet counts are low are used (exceptionally low platelet count samples), the counting method is automatically switched over to an optical method (PLT-O). In the present study, we examined the usefulness of the XE-5000 by comparing PLT-I with PLT-O, using blood samples with low platelet counts collected from patients who visited our hospital between January 1 and March 31, 2012. Dilution linearity left nothing to be desired in either of the two, but simultaneous reproducibility was higher in PLT-O than in PLT-I. The correlations of PLT-I and PLT-O with visual counts were high, working out at r＝0.889～0.984. In the exceptionally low platelet count samples, the correlation coefficient was high in PLT-O than in PLT-I. The cases showing low platelet counts frequently presented giant platelets and/or red cell fragments. Therefore, measuring the samples with low platelet counts requires a high degree of precision. In the samples with exceptionally low platelet counts, PLT-O exceeded PLT-I in simultaneous reproducibility and correlation with visual counts. Thus, our study demonstrated the usefulness of the XE-5000 that could enumerate PLT-O automatically and speedily.

  With the spread of a novel H1N1 strain of influenza A around the world, the World Health Organization declared that the situation had entered the pandemic phase. In Japan, it had a major social impact, causing a great hit to the national economy. And there is every likelihood that the H1N1 influenza is going to break out a lot of people on the staff of the agricultural cooperatives in Aichi Prefecture, seriously affecting the activities of agricultural cooperatives too. Based on the amount of damage from the flu presumed by the Japanese government and various kinds of statistical material, we worked out how much the flu would cost the agricultural co-ops in the prefecture by infecting their employees and involved their family. At an absence rate of 20%, the lowest rate presupposed by the government, our calculation showed that the extra costs would amount to 740 million yen altogether. If the rete of abscense from work was given 40%, the largest estimate by the government, the costs rocketed to highly 1.48 billion yen. A check on the situation of individual co-ops revealed that some of the co-ops would burden an extra cost of well over 100 million yen. From these findings, we concluded that to minimize the effects of the flu appropriate, effective countermeasures have to be taken after sufficient information about the novel influenza virus was collected and analyzed carefully.

It has been experienced that Kampo, with its philosophy that every disease is psychosomatic in origin and that herbs affect both the psyche and the soma, sometimes has a dramatic effect on somatoform disorders, though there has been no study examining the effects of Kampo on somatoform disorders. In this preliminary study, the morbidity of somatoform disorders among patients who visited the Keio Kampo Clinic and the patients' psychological well-being were examined.
One hundred patients (17 males and 83 females; mean age [±SD], 39±16) who sought Kampo treatment for the first time at Keio University Hospital participated in this study. A Japanese checklist derived from the somatoform disorders schedule (version 1.1) was used to check the somatoform symptoms. To assess psychological well-being, the subjective well-being inventory (SUBI) was performed. The subjects' clinical records were examined afterwards to rule out symptoms which could be medically explained.
Somatoform patients and medically ill (non-somatoform) patients were 65% and 26% of the total respectively. The somatoform patients showed significantly lower SUBI positive scores than the non-somatoform patients (p=0.042), while SUBI negative scores were significantly higher (p=0.001). Among the somatoform patients, there was a negative correlation between numbers of somatoform symptoms and SUBI positive scores (r=0.267; p=0.032), and a positive correlation between numbers of somatoform symptoms and SUBI negative scores (r=0.337; p=0.006).
Following the SUBI scores through treatment courses may lead to a better understanding of the pathology of somatoform disorders and to more effective use of Kampo.

Eighteen untreated patients with schizophrenia and other psychotic disorders, all of whom had insomnia among their chief complaints, were randomly divided into two groups. For four weeks, nine patients (group A) were treated with neuroleptics (haloperidol) and Orengedokuto, and the remainder (group B) were treated with neuroleptics alone. Changes in schizophrenic symptoms and the number of doses of hypnotics (nitrazepam) were examined. In group A, the thought disturbance (conceptual disorganization, grandiosity, hallucinatory behavior, unusual thought content) aspect of schizophrenic symptoms improved (p=0.06), and the number of doses of hypnotics (mean=1.9) was smaller (p=0.06), as compared with group B (mean=7.7). These observations suggest that augmentation therapy with Orengedoku-to is potentially effective for the treatment of insomnia associated with schizophrenia and other psychotic disorders.